A new diabetes and obesity pill that activates skeletal muscle metabolism — bypassing entirely the gut hormone pathway targeted by drugs like Ozempic and Mounjaro — has shown promising results in a first-in-human clinical trial, researchers at Massachusetts General Hospital announced Thursday, potentially broadening the obesity pharmacopeia beyond the GLP-1 class that has dominated the field since 2023.
How It Works
The experimental compound activates a protein pathway in skeletal muscle tissue called AMP-activated protein kinase, or AMPK. When AMPK is switched on, muscle cells begin burning glucose and fatty acids at an accelerated rate — mimicking, in biochemical terms, the metabolic effect of sustained aerobic exercise without requiring the patient to actually perform it. The mechanism is categorically different from semaglutide or tirzepatide, which work primarily by slowing gastric emptying and sending appetite-suppression signals to the brain through gut hormone receptors.
"What we are doing is flipping a metabolic switch that evolution built to activate during food scarcity and sustained physical exertion," said Dr. Sandra Okafor, the study's principal investigator and a senior endocrinologist at Massachusetts General in Boston. "We are targeting a completely different system than the GLP-1 drugs. That means it may work for patients who do not respond to Ozempic, and it could potentially be combined with them."
What the Trial Showed
The Phase 1 trial enrolled 48 adults with Type 2 diabetes at sites in Massachusetts and New Hampshire. Participants taking the highest dose showed a 1.4% reduction in HbA1c — a standard long-term blood sugar marker — over 12 weeks, compared to placebo. Average body weight dropped 4.1 kilograms. Crucially, gastrointestinal side effects were minimal across all dose cohorts, in contrast to the nausea, vomiting, and abdominal discomfort that cause a significant share of GLP-1 patients to discontinue treatment.
"The weight and blood sugar numbers are modest compared to semaglutide at full dose," Dr. Okafor acknowledged at a Thursday press briefing. "But this is a first-in-human study, and we are not near the maximum tolerated dose. The safety profile at this stage is the actual headline."
What the Drug Does Not Yet Do
The trial enrolled only patients with existing Type 2 diabetes. The compound has not been tested in people with obesity but no diabetes diagnosis, meaning its effectiveness as a standalone weight-loss therapy — outside a blood sugar management context — remains unknown. A Phase 2 trial, expected to begin enrollment this fall, will include adults with obesity but no metabolic disease, which will generate the first meaningful data on its pure anti-obesity application.
Researchers also flagged a known risk with AMPK-pathway drugs: earlier-generation compounds tested in the 2000s produced liver toxicity in animal studies at elevated doses. Dr. Okafor said the new compound's molecular formulation was specifically engineered to minimize hepatic uptake, but she was direct that longer-term safety data at higher doses does not yet exist.
"We are being transparent about what we do not know," she said. "Liver monitoring will be a primary endpoint in Phase 2 for that reason."
Where This Sits in the Market
The commercial stakes are enormous. Novo Nordisk and Eli Lilly have together accumulated a combined market capitalization exceeding $1 trillion largely on the strength of their GLP-1 drugs. A pill that works through a different mechanism — and that could be manufactured at significantly lower cost than injectable biologics — carries obvious implications for competition and patient access. But the regulatory bar is high, and for good historical reasons.
"The FDA has been very conservative with weight loss drugs since the fen-phen era, and appropriately so," said Dr. Kevin Marsh, a pharmacologist at Tufts University School of Medicine who was not involved in the research. "They are going to want long-term cardiovascular outcome data before granting broad approval. We are likely looking at five to seven years to market, in an optimistic scenario."
What Comes Next
The study was published Thursday in the journal Cell Metabolism. The Cambridge-based biotech company behind the compound has not yet been publicly named; the research team said a corporate announcement is expected later this summer. The Phase 2 trial design has been submitted to the FDA, and the agency's feedback is expected within 60 days.
If the mechanism holds at higher doses and the liver safety profile remains clean, the compound could represent the first genuinely differentiated obesity pharmacology to reach late-stage trials since the GLP-1 class broke through. Whether it ultimately reaches patients is a question the next several years of trials will have to answer — but Thursday's results gave researchers in the field reason to watch the AMPK pathway more carefully than they have in decades.